By Associate Professor Meg Jardine

Journal articles

Campain A; Hockham C; Sukkar L; Rogers K; Chow CK; Lung T; Jun M; Pollock C; Cass A; Sullivan D; Comino E; Peiris D; Jardine M, 2022, 'Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction', Frontiers in Pharmacology, 13, http://dx.doi.org/10.3389/fphar.2022.834898

Charytan DM; Yu J; Jardine MJ; Cannon CP; Agarwal R; Bakris G; Greene T; Levin A; Pollock C; Powe NR; Arnott C; Mahaffey KW, 2022, 'Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial', Clinical Journal of the American Society of Nephrology, 17, pp. 361 - 373, http://dx.doi.org/10.2215/CJN.08980621

Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GFM, 2022, 'Antiplatelet agents for chronic kidney disease', Cochrane Database of Systematic Reviews, 2022, http://dx.doi.org/10.1002/14651858.CD008834.pub4

Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ, 2022, 'Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial', American Journal of Kidney Diseases, 79, pp. 244 - 256.e1, http://dx.doi.org/10.1053/j.ajkd.2021.05.005

Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ, 2022, 'GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes', Kidney International, 101, pp. 360 - 368, http://dx.doi.org/10.1016/j.kint.2021.10.033

Jardine MJ; Kotwal SS; Bassi A; Hockham C; Jones M; Wilcox A; Pollock C; Burrell LM; McGree J; Rathore V; Jenkins CR; Gupta L; Ritchie A; Bangi A; D'Cruz S; McLachlan AJ; Finfer S; Cummins MM; Snelling T; Jha V, 2022, 'Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial', BMJ, 379, pp. e072175, http://dx.doi.org/10.1136/bmj-2022-072175

Clase CM; Dicks E; Holden R; Sood MM; Levin A; Kalantar-Zadeh K; Moore LW; Bartlett SJ; Bello AK; Bohm C; Bridgewater D; Bouchard J; Burger D; Carrero JJ; Donald M; Elliott M; Goldenberg MJ; Jardine M; Lam NN; Maddigan WJ; Madore F; Mavrakanas TA; Molnar AO; Prasad GVR; Rigatto C; Tennankore KK; Torban E; Trainor L; White CA; Hartwig S, 2022, 'Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action', Canadian Journal of Kidney Health and Disease, 9, http://dx.doi.org/10.1177/20543581221080327

Yi TW; Atiquzzaman M; Zheng Y; Smyth B; Jardine M; Levin A, 2022, 'Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study', Canadian Journal of Kidney Health and Disease, 9, http://dx.doi.org/10.1177/20543581221145068

Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ, 2022, 'Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial', Journal of Diabetes Investigation, 13, pp. 54 - 64, http://dx.doi.org/10.1111/jdi.13624

Young TK; Toussaint ND; Di Tanna GL; Arnott C; Hockham C; Kang A; Schutte AE; Perkovic V; Mahaffey KW; Agarwal R; Bakris GL; Charytan DM; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Zhang H; Jardine MJ, 2022, 'Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial', Journal of Diabetes Research, 2022, http://dx.doi.org/10.1155/2022/9998891

Januzzi JL; Butler J; Sattar N; Tefera E; Rosenthal N; Yavin Y; Bull S; Jardine M; Pollock C; Heerspink HJL; Hansen MK, 2022, 'INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL', Journal of the American College of Cardiology, 79, pp. 299 - 299, http://dx.doi.org/10.1016/s0735-1097(22)01290-6

Collister DT; Pyne L; Bhasin AA; Ahmed SB; Smyth B; Herrington WG; Jardine M; Walsh M, 2022, 'Sex and Gender Considerations in Randomized Controlled Trials in Adults Receiving Chronic Dialysis: A Meta-Epidemiologic Study', Journal of the American Society of Nephrology, 33, pp. 266 - 266, http://dx.doi.org/10.1681/asn.20223311s1266b

Neuen BL; Oshima M; Perkovic V; Agarwal R; Arnott C; Bakris G; Cannon CP; Charytan DM; Edwards R; Górriz JL; Jardine MJ; Levin A; Neal B; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial', European Heart Journal, 42, pp. 4891 - 4901, http://dx.doi.org/10.1093/eurheartj/ehab497

Hockham C; Kotwal S; Wilcox A; Bassi A; McGree J; Pollock C; Burrell LM; Bathla N; Kunigari M; Rathore V; John M; Lin E; Jenkins C; Ritchie A; McLachlan A; Snelling T; Jones M; Jha V; Jardine M, 2021, 'Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial', Trials, 22, pp. 573, http://dx.doi.org/10.1186/s13063-021-05521-0

Feng KY; Li JW; Ianus J; de Zeeuw D; Fulcher GR; Pfeifer M; Matthews DR; Jardine MJ; Perkovic V; Neal B; Mahaffey KW, 2021, 'Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis', Diabetes, Obesity and Metabolism, 23, pp. 2707 - 2715, http://dx.doi.org/10.1111/dom.14525

Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2021, 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics', American Journal of Nephrology, 52, pp. 827 - 836, http://dx.doi.org/10.1159/000519812

Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M, 2021, 'Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program', Diabetologia, 64, pp. 2402 - 2414, http://dx.doi.org/10.1007/s00125-021-05524-1

Neuen BL; Oshima M; Perkovic V; Arnott C; Bakris G; Cannon CP; Charytan DM; Jardine M; Levin A; Neal B; Pollock C; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', European Heart Journal, 42, pp. ehab724.2647, http://dx.doi.org/10.1093/eurheartj/ehab724.2647

Kang A; Arnold R; Gallagher M; Snelling P; Green J; Fernando M; Kiernan MC; Hand S; Grimley K; Burman J; Heath A; Rogers K; Bhattacharya A; Smyth B; Bradbury T; Hawley C; Perkovic V; Krishnan AV; Jardine MJ, 2021, 'Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1365 - 1375, http://dx.doi.org/10.2215/CJN.17151120

Wang KM; Li JW; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI, 2021, 'Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program', Endocrinology, Diabetes and Metabolism, 4, pp. e00247, http://dx.doi.org/10.1002/edm2.247

Tiong MK; Krishnasamy R; Smith ER; Hutchison CA; Ryan EG; Pascoe EM; Hawley CM; Hewitson TD; Jardine MJ; Roberts MA; Cho Y; Wong MG; Heath A; Nelson CL; Sen S; Mount PF; Vergara LA; Paul-Brent PA; Johnson DW; Toussaint ND, 2021, 'Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis', Hemodialysis International, 25, pp. 322 - 332, http://dx.doi.org/10.1111/hdi.12924

Cardoza K; Kang A; Smyth B; Yi TW; Di Tanna GL; Pollock CA; De Zeeuw D; Wheeler DC; Cannon CP; Zinman B; Jardine MJ; Arnott C; Levin A; Mahaffey KW, 2021, 'Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE', DIABETES, 70, http://dx.doi.org/10.2337/db21-133-LB

Yi TW; Smyth B; Kang A; Cardoza K; Di Tanna GL; Arnott C; Pollock CA; Agarwal R; Bakris G; Cannon CP; De Zeeuw D; Heerspink HL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2021, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-129-LB

Liao J; Kang A; Xia C; Arnott C; Di Tanna GL; Krishnan AV; Pollock CA; Agarwal R; Bakris G; Heerspink HL; Levin A; De Zeeuw D; Neal B; Zhang H; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B, 2021, 'The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-131-LB

Jun M; Harris K; Heerspink HJL; Badve SV; Jardine MJ; Harrap S; Hamet P; Marre M; Poulter N; Kotwal S; Gallagher M; Perkovic V; Chalmers J; Woodward M, 2021, 'Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial', Diabetes, Obesity and Metabolism, 23, pp. 1420 - 1425, http://dx.doi.org/10.1111/dom.14351

Ye N; Jardine MJ; Oshima M; Hockham C; Heerspink HJL; Agarwal R; Bakris G; Schutte AE; Arnott C; Chang TI; Górriz JL; Cannon CP; Charytan DM; De Zeeuw D; Levin A; Mahaffey KW; Neal B; Pollock C; Wheeler DC; Luca Di Tanna G; Cheng H; Perkovic V; Neuen BL; Di Tanna GL, 2021, 'Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial', Circulation, 143, pp. 1735 - 1749, http://dx.doi.org/10.1161/CIRCULATIONAHA.120.048740

Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; De Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI; Guerrero RAA; Aizenberg D; Albisu JP; Alvarisqueta A; Bartolacci I; Berli MA; Bordonava A; Calella P; Cantero MC; Cartasegna LR; Cercos E; Coloma GC; Colombo H; Commendatore V; Cuadrado J; Cuneo CA; Cusumano AM; Douthat WG; Dran RD; Farias E; Fernandez MF; Finkelstein H; Fragale G; Fretes JO; Garcia NH; Gastaldi A; Gelersztein E; Glenny JA; Gonzalez JP; Del Carmen Gonzalez Colaso P; Goycoa C; Greloni GC; Guinsburg A; Hermida S; Juncos LI; Klyver MI; Kraft F; Krynski F; Lanchiotti PV; De La Fuente RAL; Marchetta N; Mele P; Nicolai S; Novoa PA; Orio SI; Otreras F; Oviedo A; Raffaele P; Resk JH; Rista L; Papini NR; Sala J; Santos JC; Schiavi LB; Sessa H; Casabella TS; Ulla MR; Valdez M; Vallejos A; Villarino A; Visco VE; Wassermann A; Zaidman CJ; Cheung NW; Droste C; Fraser I; Johnson D; Mah PM; Nicholls K; Packham D; Proietto J; Roberts A; Roger S; Tsang V; Raduan RA; Da Costa FAA; Amodeo C; Turatti LAA; Bregman R; Sanches FCC; Canani LH; Chacra AR; Borges JLC; Vêncio SAC; Da Silva Franco RJ; D'Avila D; De Souza Portes E; De Souza P; Phillips A, 2021, 'Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis', Stroke, 52, pp. 1545 - 1556, http://dx.doi.org/10.1161/STROKEAHA.120.031623

Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD, 2021, 'Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program', ESC Heart Failure, 8, pp. 1482 - 1493, http://dx.doi.org/10.1002/ehf2.13236

Clase CM; Fu EL; Jardine M; Mann JFE; Carrero JJ, 2021, 'In response', Annals of Internal Medicine, 174, pp. 580, http://dx.doi.org/10.7326/L21-0091

Oshima M; Jardine MJ; Agarwal R; Bakris G; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Lim SK; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V; Heerspink HJL, 2021, 'Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice', Kidney International, 99, pp. 999 - 1009, http://dx.doi.org/10.1016/j.kint.2020.10.042

Nataatmadja M; Krishnasamy R; Zuo L; Hong D; Smyth B; Jun M; de Zoysa JR; Howard K; Wang J; Lu C; Liu Z; Chan CT; Cass A; Perkovic V; Jardine M; Gray NA, 2021, 'Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis', Kidney International Reports, 6, pp. 1058 - 1065, http://dx.doi.org/10.1016/j.ekir.2021.01.020

Ng JKC; Smyth B; Marshall MR; Kang A; Pinter J; Bassi A; Krishnasamy R; Rossignol P; Rocco MV; Li Z; Jha V; Hawley CM; Kerr PG; Di Tanna GL; Woodward M; Jardine AM, 2021, 'Relationship between measured and prescribed dialysate sodium in haemodialysis: A systematic review and meta-Analysis', Nephrology Dialysis Transplantation, 36, pp. 695 - 703, http://dx.doi.org/10.1093/ndt/gfaa287

Sarraju A; Li JW; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW, 2021, 'Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial', American Heart Journal, 233, pp. 141 - 148, http://dx.doi.org/10.1016/j.ahj.2020.12.008

Barisoni L; Barratt J; Campbell K; Eva L; Gillespie BS; Gipson D; Huber T; Jardine M; Kamil E; Kretzler M; Lee L; Levtchenk E; Mehr AP; Nachman PH; Oh J; Saleem M; Shankland SJ; Smith K; Smokler I; Smoyer W; Tarnoff J; Thompson A; Trachtman H; Udani S; Vivarelli M; Walker P; West M; Rovin BH, 2021, 'Innovating and invigorating the clinical trial infrastructure for glomerular diseases', Kidney International, 99, pp. 519 - 523, http://dx.doi.org/10.1016/j.kint.2020.09.038

O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V, 2021, 'The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes', Diabetes, Obesity and Metabolism, 23, pp. 763 - 773, http://dx.doi.org/10.1111/dom.14281

Evans RDR; Smyth B; Levin A; Jha V; Wheeler DC; Jardine M; Perkovic V; Damster S; Malik C; de Zeeuw D; Hiemstra T, 2021, 'The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals', Kidney International, 99, pp. 551 - 554, http://dx.doi.org/10.1016/j.kint.2020.10.048

Yu J; Zhou Z; Mahaffey KW; Matthews DR; Neuen BL; Heerspink HJL; Jardine MJ; Li JW; Perkovic V; Neal B; Arnott C, 2021, 'An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials', International Journal of Cardiology, 324, pp. 165 - 172, http://dx.doi.org/10.1016/j.ijcard.2020.09.050

Oshima M; Hara A; Toyama T; Jun M; Pollock C; Jardine M; Harrap S; Poulter N; Cooper ME; Woodward M; Chalmers J; Perkovic V; Wong MG; Wada T, 2021, 'Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor', Kidney International Reports, 6, pp. 284 - 295, http://dx.doi.org/10.1016/j.ekir.2020.10.039

Kang A; Jardine MJ, 2021, 'SGLT2 inhibitors may offer benefit beyond diabetes', Nature Reviews Nephrology, 17, pp. 83 - 84, http://dx.doi.org/10.1038/s41581-020-00391-2

Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL, 2021, 'Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes', Diabetes, Obesity and Metabolism, 23, pp. 382 - 390, http://dx.doi.org/10.1111/dom.14226

Athavale A; Morris J; Jardine M; Gallagher M; Sen S; Ritchie A; Wang AY, 2021, 'Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide', Nephrology, 26, pp. 12 - 14, http://dx.doi.org/10.1111/nep.13783

Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2021, 'Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis', Clinical Journal of the American Society of Nephrology, 16, pp. 384 - 395, http://dx.doi.org/10.2215/CJN.15260920

Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC, 2021, 'Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program', American Journal of Kidney Diseases, 77, pp. 23 - 34.e1, http://dx.doi.org/10.1053/j.ajkd.2020.06.018

Li C; Zhou Z; Neuen BL; Yu J; Huang Y; Young T; Li J; Li L; Perkovic V; Jardine MJ; Keay L; Markoulli M; Rosenthal N; Capuano G; Yavin Y; Neal B; Arnott C, 2021, 'Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, 23, pp. 252 - 257, http://dx.doi.org/10.1111/dom.14197

Neuen BL; Jardine MJ; Perkovic V, 2021, 'Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?', Nephrology Dialysis Transplantation, 35, pp. I48 - I55, http://dx.doi.org/10.1093/NDT/GFZ252

Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD, 2021, 'Corrigendum', ESC Heart Failure, 8, pp. 3447 - 3447, http://dx.doi.org/10.1002/ehf2.13408

Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V, 2020, 'Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m²: Subgroup analysis of the randomized CREDENCE trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1705 - 1714, http://dx.doi.org/10.2215/CJN.10140620

Oshima M; Neuen BL; Li JW; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; de Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial', Journal of the American Society of Nephrology, 31, pp. 2925 - 2936, http://dx.doi.org/10.1681/ASN.2020050723

Sukkar L; Young T; Jardine MJ, 2020, 'How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?', Kidney and Blood Pressure Research, 45, pp. 823 - 836, http://dx.doi.org/10.1159/000511214

Zhang H; Rogers K; Sukkar L; Jun M; Kang A; Young T; Campain A; Cass A; Chow CK; Comino E; Foote C; Gallagher M; Knight J; Liu B; Lung T; McNamara M; Peiris D; Pollock C; Sullivan D; Wong G; Zoungas S; Jardine M; Hockham C, 2020, 'Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data', Journal of Clinical and Translational Endocrinology, 22, pp. 100240, http://dx.doi.org/10.1016/j.jcte.2020.100240

Back to profile page